Background:To investigate the potential active ingredients and possible mechanisms of Shujin Tongluo granules (SJTLG) in the treatment of cervical spondylosis (CS) by network pharmacology and molecular docking.Methods:The active ingredients and potential targets of SJTLG were obtained through databases such as traditional Chinese medicine system (TCMSP) and BATMAN-traditional Chinese medicine (TCM), and the relevant human targets of CS were identified through databases such as OMIM, GeneCards, and DisGeNET. The intersection targets were imported into STRING for protein-protein interaction (PPI) analysis. The obtained data were imported into Cytoscape 3.9.0 software for visualization, and module analysis was performed using the MCODE plug-in. The representative targets were screened through the Metascape website for pathway enrichment analysis in Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). Cytoscape software was used to build networks such as “drug-compound-target” and “drug-compound-target-pathway.” Finally, the key targets were selected for molecular docking with the corresponding compounds by Autodock Tools 1.5.7 and visualized by PyMol.Results:A total of 132 active compounds and 996 targets from SJTLG and 678 targets from CS were screened with 116 intersection targets. The key targets were AKT1, GAPDH, ALB, IL-6, TP53, TNF, VEGFA, IL-1β, EGFR, HSP90AA1, ESR1, and JUN. The results of GO and KEGG enrichment analysis showed that the treatment of CS was mainly related to biological processes such as cellular response to nitrogen compound, cellular response to organonitrogen compound, and positive regulation of locomotion, and the targets were mainly focused on pathways in cancer, Kaposi sarcoma-associated herpesvirus infection, PI3K-Akt signaling pathway, lipid, and atherosclerosis. Molecular docking results showed that the minimum binding energy between the core targets and the corresponding compound was <−5.0 kcal·mol−1.Conclusion:This study preliminarily elucidates the potential active ingredients and mechanism of anti-inflammatory, analgesic, microcirculation improvement, vasodilation, osteoporosis inhibition and nerve nutrition effects of SJTLG in the treatment of CS and provides a reference for its clinical application.

2020-01-25·Zhongguo gu shang = China journal of orthopaedics and traumatology

[Effect of Tongdu Shujin Decoction () plus Lijin () manipulation on degenerative lumbar spinal stenosis].

Article

作者: Zhou, Xiao-Hong ; Peng, Rui ; Zheng, Jian-Nan ; Chen, Hong-Bo

OBJECTIVETo explore the clinical efficacy of Tongdu Shujin Decoction (, TSD) combined with manipulation for the treatment of lumbar spinal stenosis.METHODSThe clinical data of 50 patients with lumbar spinal stenosis diagnosed from October 2015 to October 2017 were retrospectively studied. Fifty patients were divided into a treatment group and a control group, 25 cases in each group. In the treatment group, 25 patients were treated by TSD plus combined manipulation, including 10 males and 15 females, with an average age of (53.43±5.26) years old, the course of disease was (6.9± 2.3) years. In the control group, 25 patients were treated by the adenosine cobalamin tablets and loxoprofen sodium tablets, including 12 males and 13 females, with an average age of (56.37±4.61) years old, the course of disease was (7.1±3.4) years. The two groups were treated for 4 weeks. After treatment, the clinical efficacy of the two groups were evaluated by the low back pain evaluation criteria (JOA) and visual analogue scale (VAS) .RESULTSFifty patients were followed up for 2.2 to 3.2 (2.62± 0.47) months. After treatment, JOA and VAS scores of the two groups were significantly improved compared with those before treatment, the difference was statistically significant (P<0.01) , and the improvement degree of the treatment group was better than that of the control group, the difference was statistically significant (P<0.01) .CONCLUSIONTSD combined with manipulation for the treatment of lumbar spinal stenosis has a good effect.

2010-11-01·Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine

[Effects of Huatan Tongluo Granule on SOCS-3 and TNF-alpha expressions in patients with acute cerebral infarction].

Article

作者: Fang, Mei-Feng ; Zhang, Xin ; Tan, Feng

OBJECTIVETo observe the effect of Huatan Tongluo Granule (HTG) on the expression of suppressors of cytokine signaling-3 (SOCS-3) and tumor necrosis factor-alpha (TNF-alpha) in patients with acute cerebral infarction (ACI) of phlegm-wind-stasis obstruction (PWSO) syndrome type.METHODSSixty-six ACI patients of PWSO type admitted within 72 h were randomized into the treatment group (34 cases) and the control group (32 cases), they were treated with foundational therapeutics, but HTG was given additionally to patients in the treatment group. SOCS-3 expression was detected by ELISA before treatment (d0) and on the 3rd (d3) and 7th day (d7) of treatment; TNF-alpha expression was detected by chemiluminescence at dO and d7. Data were compared with the respective parameters obtained from 20 healthy persons as normal control. Meantime, the degree of neuro-deficit in the two groups was evaluated by NIH Stroke scale and Barthel index on d0, d7, d14 and d21.RESULTSSOCS-3 expression at d0, d3, d7; and TNF-alpha expression at d0, d7 were higher in the two patients' groups significantly than in normal controls (P < 0.05). As compared with the control group, on d7, SOCS-3 expression was higher (360.98 +/- 123.31 ng/L vs. 281.87 +/- 133.66 ng/L) and TNF-alpha expression was lower (35.72 +/- 19.94 ng/L vs. 49.86 +/- 34.79 ng/L), while the NIHSS score on d7 and d14, as well as the Barthel index on d14 and d21 were lower in the treatment group (all P < 0.05).CONCLUSIONSThe acting mechanism of HTG for promoting nerve function recovery of ACI patients is possibly and closely related with the up-regulation of the inflammation suppressive factor SOCS-3, the down-regulation of the inflammation promoting factor TNF-alpha, and the elimination of secondary inflammatory injury after cerebral ischemia.

项与舒筋通络颗粒相关的新闻（医药）

2024-06-24

·蒲公英Ouryao

药典委：又公示5个中药标准草案

转自：国家药典委编辑：水晶近日，国家药典委公示了15个中药标准草案。 6月24日，国家药典委又公示5个中药标准草案：舒筋通络颗粒、阿胶、连苏胶囊、黄莪胶囊、茜草、痹祺胶囊。修订内容：舒筋通络颗粒： 1、【处方】将处方量总3360g变更为2240g，制成总量保持1000g不变。 2、【规格】【用法与用量】结合处方量及制成总量，将原“每袋装12g”“开水冲服，一次一袋”分别修改为“每1g相当于饮片2.24g”“开水冲服，一次18g”，调整后日服饮片量保持一致。 3、【鉴别】、【检查】及【含量测定】取样量：结合产品规格变化情况，相应增加取样量。 4、【含量测定】修订含量测定指标范围，柚皮苷含量范围0.67~1.65mg/g，天麻素含量范围0.50~1.10mg/g，葛根素含量范围3.2~9.8mg/g。阿胶：增订阿胶饮片鉴别、重金属及有害元素、含量测定项；增订阿胶珠饮片重金属：及有害元素检查项、特征多肽含量测定项。茜草：茜草药材新增粉末显微鉴别，修订薄层鉴别中对照品溶液浓度；茜草饮片同步修订，茜草炭饮片修订浸出物限度。痹祺胶囊 1.修订了制剂中马钱子含量测定方法。 2.修订了所附马钱子粉制法及鉴别方法，修订了含量测定方法及限度。 3.根据《中成药规格表述技术指导原则》，将规格规范为“每粒装0.3g（相当于饮片0.3g）” 连苏胶囊、黄莪胶囊公示稿：更多内容，点击“阅读原文”下载。

100 项与舒筋通络颗粒相关的药物交易

登录后查看更多信息